INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,391,949 | +17.1% | 26,722 | +42.3% | 0.01% | 0.0% |
| Q2 2023 | $1,189,150 | +284.9% | 18,780 | +229.2% | 0.01% | +400.0% |
| Q1 2023 | $308,926 | +1.4% | 5,705 | -0.9% | 0.00% | -50.0% |
| Q4 2022 | $304,714 | +444.1% | 5,758 | +485.2% | 0.00% | – |
| Q2 2022 | $56,000 | -8.2% | 984 | -2.1% | 0.00% | – |
| Q1 2022 | $61,000 | +29.8% | 1,005 | +10.9% | 0.00% | – |
| Q4 2021 | $47,000 | +88.0% | 906 | +34.2% | 0.00% | – |
| Q3 2021 | $25,000 | +4.2% | 675 | +15.4% | 0.00% | – |
| Q2 2021 | $24,000 | +20.0% | 585 | 0.0% | 0.00% | – |
| Q1 2021 | $20,000 | +100.0% | 585 | +95.0% | 0.00% | – |
| Q4 2020 | $10,000 | +25.0% | 300 | 0.0% | 0.00% | – |
| Q3 2020 | $8,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q2 2020 | $8,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |